Rose Bengal photodynamic antimicrobial therapy as an adjunct treatment for Pseudomonas aeruginosa infectious necrotizing scleritis
Purpose To report the utility of Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) as an adjunct treatment in rapidly progressing Infectious Necrotizing Scleritis (INS) secondary to Pseudomonas aeruginosa. Methods Retrospective chart review was conducted on consecutive patients with scleritis...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Photodiagnosis and Photodynamic Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1572100025001048 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Purpose To report the utility of Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) as an adjunct treatment in rapidly progressing Infectious Necrotizing Scleritis (INS) secondary to Pseudomonas aeruginosa. Methods Retrospective chart review was conducted on consecutive patients with scleritis and culture-proven Pseudomonas aeruginosa who underwent RB-PDAT. Results Six patients with Pseudomonas aeruginosa INS were included. All patients achieved complete resolution of the infection. The mean time to resolution after RB-PDAT was 17 days (range; 6–30 days), with a total treatment course average of 36 days (range; 22–60 days). One patient with pan-resistant Pseudomonas sclerokeratitis required two RB-PDAT treatments due to persistent stromal melting. All patients received a standardized regimen of oral fluoroquinolone, topical tobramycin, and ciprofloxacin/moxifloxacin. The patient with pan-resistant Pseudomonas aeruginosa required treatment with topical imipenem as well. None of the patients required enucleation. Conclusion RB-PDAT is a feasible option to halt the progression of infectious necrotizing scleritis caused by Pseudomonas aeruginosa, especially in cases of impending perforation. |
|---|---|
| ISSN: | 1572-1000 |